Pediatric Dermatology Clinic now accepting referrals for complex cases
-
May 14, 2026
-
1 min
May 14, 2026
The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.
June 30, 2026
Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.
June 29, 2026
A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.
by Kerri Miller
April 16, 2026